Author(s): Gonçalves, Mariana ; Matos, Liliana ; Santos, Juliana I. ; Coutinho, Maria Francisca ; Prata, Maria João ; Pires, Maria João ; Oliveira, Paula ; Omidi, Maryam ; Pohl, Sandra ; Alves, Sandra
Date: 2023
Persistent ID: http://hdl.handle.net/10400.18/9144
Origin: Repositório Científico do Instituto Nacional de Saúde
Subject(s): Mucolipidosis II; Lysosomal Storage Disorder; Genética Humana; Doenças Genéticas; Rare Disease
Mucolipidosis II (MLII) is a Lysosomal Storage Disorder caused by the deficiency of the enzyme GlcNAc-1-phosphotransferase, which is responsible for the Mannose- 6-Phosphate marker addition to lysosomal enzymes. Of all MLII mutations, the c.3503_3504delTC in GNPTAB exon 19 is the most frequent, making it a good target for a personalized therapy. Here, we explored an innovative therapeutic strategy based on the use of antisense oligonucleotides (ASOs) for MLII. Previously, on MLII patients’ fibroblasts, ASOs were used to skip exon 19 of the GNPTAB pre-mRNA, successfully resulting in the production of an in-frame mRNA[1]. Now, our aim is to analyze if these results are translated to the enzymatic and cellular phenotype level.
